The Democratic Republic of Congo (DRC, former Zaire) in central Africa remains the foremost country for leprosy in Africa, with a total of 4877 registered cases, of which 4573 are new cases since 1997. These numbers are well above the regional average. About 94% of these patients are under multidrug therapy (MDT) coverage in the Congo, which ranks 8th in coverage rate among the sur rounding nine nations. Available data on anatomo-clinical profile and bacillarity are provided, with reservations on the use of these data drwn due to relatively small sample sizes. The seroprofile of the disease was reviewed with regard to the association of other immunity impairing infections like HBV infection and the recently highly incident retroviral epidemics (HIV-1, HTLV-1. and HTLV-2).
The leading role of non-governmental organizations is cited for improving leprosy patient condi tions and also for future prospects, where the necessity of coordinated strategies with the government is emphasized. Recommendations for new trends and steps relevant to improving existing and future leprosy control strategies are put into perspective. Historically The anatomoclinical profile depicted in Table   2 shows the existence of all forms of leprosy in the DRC with a preponderance of the leproma tous form (LL) followed by the tuberculoid form (TT).
B. Bacillarity profiles of leprosy in the DRC
With regard to the bacillarity, the classifica tion of leprosy by Ridley and Jopling is used in the DRC. Although recent data are not avail able, older information indicates that the separa tion of paucibacillarity (PB) and multibacillarity (MB) is subjected to variable factors not com pletely studied to reach agreement (Table 5 Table 5 and that of the Damien foundation in Kisangani (4) used similar methodologies and were sepa rated only by one to two years, and therefore providing the feasibility of correlative study.
C. Serological profiles of leprosy index cases in correlation with other viral diseases 1) Micobacterium leprae specific antigenemia It has been established that Mycobacterium leprae specific antigens are among the key fac tors underlying the inadequate response of the leprosy patient immune system (4). This is espe cially true for phenolic glycolipid-1 (PGL-1) and glycoprotein lipoarabinomannan (LAM). Table 3 gives a general serologic pattern of 57 index cases regarding those two M. leprae antigens. Although the distribution of cases into polar and border Table2. ANATOMOCLINICAL PROFILE OF LEPROSY IN THE DRC. Note the predomi nance of the LL form. Indeterminate forms of leprosy have also been described in the DRC.
LEPROMATOUS (LL) > TUBERCULOID (TT) > BORDERLINE (B) > PRIMARY NEURITIC (PN) > INDETERMINATE (I) 2. VERY LATE PRESENTATION (DEFORMITIES)
line forms is not indicated, the result in Table 3 is in accord with the high prevalence of PGL-1
and LAM found elsewhere in Africa, among the high bacillary index lepromatous cases (4).
2) Micobacterium leprae antigenemia and viral (80.7%) were however detected more often with sera of leprosy patients than with those of the general pululation. The significance of cross re activities are given in Table 3 . At the end of the 1980s, some studies sug gested that these retroviruses might also be prevalent in Africa and seroepidemiologic screen ings found different patterns of high antibody titles in several African cities (6, 7) . In this pilot was used as an index to evaluate the situation in the rest of the country for which data are even more difficult to obtain (Table 5) . Table 4 . HBV SEROPROFILES IN DRC LEPROSY PATIENTS AND CONTACTS Note the infection with HBV does not seem to be a risk factor for leprosy. Larger series are necessary to sustain these findings. HbsAg: Hepatite B surface antigene.
Pre-S1 and Pre-S2: 2 coding regions of the HBV genome.
In the country as a whole, the number of new cases (meaning cases newly diagnosed and never treated) is on the rise in 1997 (4573, Table 1 
